Dangolsheim, France

Audrey Fluck

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Audrey Fluck: Innovator in Neuropharmacology

Introduction

Audrey Fluck is a prominent inventor based in Dangolsheim, France. She has made significant contributions to the field of neuropharmacology, particularly through her innovative research on nicotinic acetylcholine receptors. Her work focuses on developing compounds that can positively modulate these receptors, which play a crucial role in various neurological functions.

Latest Patents

Audrey Fluck holds a patent titled "Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof." This invention relates to compounds that are useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7nAChR). The patent outlines the potential applications of these compounds in treating or preventing a wide range of diseases, including neurodegenerative and neuropsychiatric disorders, as well as inflammatory diseases. She has 1 patent to her name.

Career Highlights

Fluck's career is marked by her dedication to advancing the understanding of neuropharmacology. She has worked extensively on the therapeutic implications of her research, aiming to provide new treatment options for patients suffering from complex neurological conditions. Her innovative approach has garnered attention in the scientific community.

Collaborations

Audrey collaborates with notable colleagues, including Andrew John Harvey and Bruno Giethlen. These partnerships enhance her research efforts and contribute to the development of effective therapeutic strategies.

Conclusion

Audrey Fluck is a trailblazer in the field of neuropharmacology, with her innovative work on nicotinic acetylcholine receptors paving the way for new treatment possibilities. Her contributions are vital in addressing the challenges posed by neurodegenerative and neuropsychiatric diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…